A Randomized, Double Blind, Placebo-Controlled Dose Escalation Study to Investigate the Safety and Pharmacokinetics After Single and Multiple Doses of SLV334 in Sequential Cohorts of Patients With Moderate and Severe Traumatic Brain Injury.

Trial Profile

A Randomized, Double Blind, Placebo-Controlled Dose Escalation Study to Investigate the Safety and Pharmacokinetics After Single and Multiple Doses of SLV334 in Sequential Cohorts of Patients With Moderate and Severe Traumatic Brain Injury.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2016

At a glance

  • Drugs SLV 334 (Primary)
  • Indications Brain injuries
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 04 Jul 2012 New source identified and integrated (European Clinical Trials Database, EudraCT2008-001409-40).
    • 25 Aug 2011 Additional lead trial investigator (Juliana Bronzowa) identified as reported by ClinicalTrials.gov.
    • 25 Aug 2011 Planned end date changed from 1 Sep 2010 to 1 Aug 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top